Literature DB >> 19894763

Different changes in protein and phosphoprotein levels result from serum starvation of high-grade glioma and adenocarcinoma cell lines.

Victor A Levin1, Sonali C Panchabhai, Li Shen, Steven M Kornblau, Yihua Qiu, Keith A Baggerly.   

Abstract

Tumor cells undergoing serum starvation in vitro partially mimic metabolically stressed cells trying to adjust to a changed environment in vivo by inducing signal transduction and gene expression so that the tumor continues to grow. Our hypothesis is that the changes in protein and phosphoprotein levels after serum starvation may reflect the adapted phenotype of the tumor, which could be targeted for therapy. We used reverse-phase protein microarrays to interrogate five high-grade glioma cell lines and seven adenocarcinoma cell lines for differences in the level of 81 proteins and 25 phosphoproteins. All cell lines were studied in the well-fed condition of growth with 10% FBS and the starved condition of 0.5% FBS. Protein expression levels were normalized to beta-actin and trichotomized as increased (+1, upper 75th quartile), decreased (-1, lowest 25th quartile), or unchanged (0, others) to focus on the patterns of the biggest (and hopefully most robust) changes in protein and phosphoprotein levels. We examined these trichotomized values to better understand Starved-Fed differences among the cell lines and thereby gain better/clearer insight into the effects of serum starvation on potential cellular responses. In general, the expression of proteins and phosphoproteins 24 h after FBS starvation increased more often in glioma lines than in adenocarcinoma lines, which appeared to have fewer increased protein scores and more decreased scores. Many of the proteins increased in gliomas were downstream targets of the PTEN-PI-3 kinase-AKT, EGFR-MAPK-Stat, and transcription activator-polyamine signaling pathways. In adenocarcinomas, the expression of proteins and phosphoproteins generally increased in apoptosis pathways, while there were minor fluctuations in the other pathways above. Contrawise, gliomas become resistant to apoptosis after 24 h of serum starvation and upregulate transcription activators and polyamines more so than adenocarciomas.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19894763      PMCID: PMC3386607          DOI: 10.1021/pr900392b

Source DB:  PubMed          Journal:  J Proteome Res        ISSN: 1535-3893            Impact factor:   4.466


  33 in total

1.  The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation.

Authors:  J Momand; G P Zambetti; D C Olson; D George; A J Levine
Journal:  Cell       Date:  1992-06-26       Impact factor: 41.582

2.  erg, an ets-related gene, codes for sequence-specific transcriptional activators.

Authors:  E S Reddy; V N Rao
Journal:  Oncogene       Date:  1991-12       Impact factor: 9.867

Review 3.  Ets transcription factors: nuclear effectors of the Ras-MAP-kinase signaling pathway.

Authors:  B Wasylyk; J Hagman; A Gutierrez-Hartmann
Journal:  Trends Biochem Sci       Date:  1998-06       Impact factor: 13.807

4.  Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53.

Authors:  R Honda; H Tanaka; H Yasuda
Journal:  FEBS Lett       Date:  1997-12-22       Impact factor: 4.124

5.  RNA-binding protein Musashi family: roles for CNS stem cells and a subpopulation of ependymal cells revealed by targeted disruption and antisense ablation.

Authors:  Shin-ichi Sakakibara; Yuki Nakamura; Tetsu Yoshida; Shinsuke Shibata; Masato Koike; Hiroshi Takano; Shuichi Ueda; Yasuo Uchiyama; Tetsuo Noda; Hideyuki Okano
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-29       Impact factor: 11.205

6.  Dual roles of Nur77 in selective regulation of apoptosis and cell cycle by TPA and ATRA in gastric cancer cells.

Authors:  Qiao Wu; Su Liu; Xiao-feng Ye; Zhi-wei Huang; Wen-jin Su
Journal:  Carcinogenesis       Date:  2002-10       Impact factor: 4.944

7.  Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D-dependent kinase CDK4.

Authors:  J Kato; H Matsushime; S W Hiebert; M E Ewen; C J Sherr
Journal:  Genes Dev       Date:  1993-03       Impact factor: 11.361

8.  Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma.

Authors:  Melissa Alsina; Rafael Fonseca; Edward F Wilson; A Nelida Belle; Elvira Gerbino; Tammy Price-Troska; Rose M Overton; Gregory Ahmann; Laura M Bruzek; Alex A Adjei; Scott H Kaufmann; John J Wright; Daniel Sullivan; Benjamin Djulbegovic; Alan B Cantor; Philip R Greipp; William S Dalton; Saïd M Sebti
Journal:  Blood       Date:  2004-01-15       Impact factor: 22.113

9.  Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B.

Authors:  D A Cross; D R Alessi; P Cohen; M Andjelkovich; B A Hemmings
Journal:  Nature       Date:  1995 Dec 21-28       Impact factor: 49.962

Review 10.  PI3K/Akt signalling pathway and cancer.

Authors:  Juan Angel Fresno Vara; Enrique Casado; Javier de Castro; Paloma Cejas; Cristóbal Belda-Iniesta; Manuel González-Barón
Journal:  Cancer Treat Rev       Date:  2004-04       Impact factor: 12.111

View more
  32 in total

1.  Serum deprivation elevates the levels of microvesicles with different size distributions and selectively enriched proteins in human myeloma cells in vitro.

Authors:  Li Sun; Hong-xiang Wang; Xiao-jian Zhu; Pin-hui Wu; Wei-qun Chen; Ping Zou; Qiu-bai Li; Zhi-chao Chen
Journal:  Acta Pharmacol Sin       Date:  2013-12-30       Impact factor: 6.150

2.  Selective enrichment of newly synthesized proteins for quantitative secretome analysis.

Authors:  Katrin Eichelbaum; Markus Winter; Mauricio Berriel Diaz; Stephan Herzig; Jeroen Krijgsveld
Journal:  Nat Biotechnol       Date:  2012-09-23       Impact factor: 54.908

3.  Tamoxifen differentially regulates miR-29b-1 and miR-29a expression depending on endocrine-sensitivity in breast cancer cells.

Authors:  Penn Muluhngwi; Abirami Krishna; Stephany L Vittitow; Joshua T Napier; Kirsten M Richardson; Mackenzie Ellis; Justin L Mott; Carolyn M Klinge
Journal:  Cancer Lett       Date:  2016-12-13       Impact factor: 8.679

4.  Hepatocellular carcinoma redirects to ketolysis for progression under nutrition deprivation stress.

Authors:  Tingting Li; Lin Wang; Long Zhang; Ronghui Yan; Kui Li; Songge Xing; Gongwei Wu; Lan Hu; Weidong Jia; Sheng-Cai Lin; Chi V Dang; Libing Song; Ping Gao; Huafeng Zhang
Journal:  Cell Res       Date:  2016-09-20       Impact factor: 25.617

5.  Conditioned Media Downregulates Nuclear Expression of Nrf2.

Authors:  Saheli Sarkar; Christine K Payne; Melissa L Kemp
Journal:  Cell Mol Bioeng       Date:  2013-06-01       Impact factor: 2.321

Review 6.  Phosphoproteomics in cancer.

Authors:  H C Harsha; Akhilesh Pandey
Journal:  Mol Oncol       Date:  2010-09-26       Impact factor: 6.603

Review 7.  Cancer secretomics reveal pathophysiological pathways in cancer molecular oncology.

Authors:  George S Karagiannis; Maria P Pavlou; Eleftherios P Diamandis
Journal:  Mol Oncol       Date:  2010-09-16       Impact factor: 6.603

8.  Δ2-Troglitazone promotes cytostatic rather than pro-apoptotic effects in breast cancer cells cultured in high serum conditions.

Authors:  Audrey Berthe; Stéphane Flament; Stéphanie Grandemange; Marie Zaffino; Michel Boisbrun; Sabine Mazerbourg
Journal:  Cell Cycle       Date:  2016-10-18       Impact factor: 4.534

9.  AMPK reverses the mesenchymal phenotype of cancer cells by targeting the Akt-MDM2-Foxo3a signaling axis.

Authors:  Chih-Chien Chou; Kuen-Haur Lee; I-Lu Lai; Dasheng Wang; Xiaokui Mo; Samuel K Kulp; Charles L Shapiro; Ching-Shih Chen
Journal:  Cancer Res       Date:  2014-07-03       Impact factor: 12.701

10.  MicroRNA-874-mediated inhibition of the major G1/S phase cyclin, CCNE1, is lost in osteosarcomas.

Authors:  Tanushree Ghosh; Akhil Varshney; Praveen Kumar; Manpreet Kaur; Vipin Kumar; Ritu Shekhar; Raksha Devi; Priyanka Priyanka; Md Muntaz Khan; Sandeep Saxena
Journal:  J Biol Chem       Date:  2017-11-06       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.